Research Article | Open Access
Antje Bruckbauer, Jheelam Banerjee, Lizhi Fu, Fenfen Li, Qiang Cao, Xin Cui, Rui Wu, Hang Shi, Bingzhong Xue, Michael B. Zemel, "A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice", International Journal of Hepatology, vol. 2016, Article ID 9185987, 16 pages, 2016. https://doi.org/10.1155/2016/9185987
A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice
Sirt1, AMPK, and eNOS modulate hepatic energy metabolism and inflammation and are key players in the development of NASH. L-leucine, an allosteric Sirt1 activator, synergizes with low doses of metformin or sildenafil on the AMPK-eNOS-Sirt1 pathway to reverse mild NAFLD in preclinical mouse models. Here we tested a possible multicomponent synergy to yield greater therapeutic efficacy in NAFLD/NASH. Liver cells and macrophages or an atherogenic diet induced NASH mouse model was treated with two-way and three-way combinations. The three-way combination Sild-Met-Leu increased hepatic fatty acid oxidation and reduced lipogenic gene expression and inflammatory marker in vitro. In mice, Sild-Met-Leu reduced the diet induced increases of ALT, TGFβ, PAI-1, IL1β, and TNFα, hepatic collagen expression, and nearly completely reversed hepatocyte ballooning and triglyceride accumulation, while all two-way combinations had only modest effects. Therefore, these data provide preclinical evidence for therapeutic efficacy of Sild-Met-Leu in the treatment of NAFLD and NASH.
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), is characterized by the presence of >5% macrovesicular steatosis, inflammation, and liver cell ballooning . Its prevalence is increasing concomitantly with prevalence of obesity and diabetes, thus representing a serious public health issue [2, 3]. About 30 to 40% of NASH progresses to fibrosis or to cirrhosis, resulting in a high risk for cardiovascular and liver-related morbidity and mortality . However, treatment is presently limited to lifestyle intervention, as approved treatment options are lacking and represent a significant unmet need.
Sirt1 enzyme and AMPK are important regulators of energy metabolism and modulate hepatic glucose and lipid metabolism. In addition, Sirt1 regulates multiple inflammatory pathways such as NF-κB and TNFα . Thus they play an important role in the pathophysiology of NAFLD and NASH [2, 4, 5]. Liver-specific deletion of Sirt1 results in hepatic steatosis and inflammation in mice , while treatment with Sirt1 activators or Sirt1 overexpression ameliorates fatty liver and reduces lipogenic gene expression [5, 7].
We have previously demonstrated that leucine acts as a direct Sirt1 activator by lowering the activation energy for NAD+ and enables coactivation with other AMPK/Sirt1 activators thereby reducing the necessary concentration for each individual compound [8, 9]. Synergy with leucine was also demonstrated with metformin (met), the first-line treatment drug for diabetes, at which effects are also mediated by merging on the AMPK/Sirt1 pathway [10, 11]. Accordingly, treatment with a Met-Leu combination resulted in reduction of lipid accumulation in vitro and reversal of hepatic steatosis in vivo in a HFD-induced NAFLD mouse model .
The endothelial nitric oxide synthase, nitric oxide and cyclic guanosine monophosphate (eNOS-NO-cGMP) signaling pathway has also been shown to affect the progression of NAFLD to NASH. High-fat diet feeding reduced eNOS-NO signaling in the liver of NAFLD models of mice and rats. This was precedent to the onset of hepatic inflammation and insulin resistance and was prevented by daily administration of sildenafil [13, 14].
The primary action of sildenafil is the inhibition of phosphodiesterase 5 (PDE5) which hydrolyses cGMP and thus terminates cGMP signaling. In addition, sildenafil activates eNOS resulting in increased NO/cGMP signaling with consecutive activation of the cGMP-dependent protein kinases (PKGs) to induce vasodilatory, anti-inflammatory, and antiproliferative effects [15–18].
This pathway also interacts with the sirtuin pathway, as it stimulates Sirt1, while Sirt1 appears to deacetylate and activate eNOS and thereby elevate NO levels; thus sildenafil’s effects may be partly mediated by Sirt1 activation [17, 19–21]. Moreover, leucine synergizes with PDE5 inhibitors to exert amplifying downstream effects of AMPK and Sirt1 activation on glucose and fat metabolism as well as reversal of hepatic steatosis and inflammation in vitro and in vivo . Accordingly, the aim of this study was to evaluate the effects of a three-way interaction between leucine, metformin, and sildenafil on AMPK/Sirt1/eNOS pathway and the protective effects on hepatocyte metabolism in a NASH mouse model.
2.1. Cell Culture
Human hepatoma HepG2 cells (ATCC, Manassas, VA, USA) were grown in Dulbecco’s modified Eagle’s medium (DMEM, 5.5 mM glucose) containing 10% fetal bovine serum (FBS) and antibiotics (1% penicillin-streptomycin) at 37°C in 5% CO2 in air. Mouse AML-12 liver cells (ATCC, Manassas, VA, USA) were grown and maintained in 1 : 1 mixture of DMEM and Ham’s F12 medium with 0.005 mg/mL insulin, 0.005 mg/mL transferrin, 5 ng/mL selenium, 40 ng·mL dexamethasone, 10% FBS, and antibiotics (1% penicillin-streptomycin) at 37°C in 5% CO2 in air. Mouse RAW 264.7 macrophages (ATCC, Manassas, VA, USA) were grown and maintained in DMEM containing 10% fetal bovine serum (FBS) and antibiotics (1% penicillin-streptomycin) at 37°C in 5% CO2 in air. Media were replaced with fresh medium every 2 to 3 days. Cells were split at a 1 : 4 ratio at 70 to 80% confluence.
Lipid accumulation in HepG2 cells was induced by incubation in 25 mM glucose DMEM media for 48 hours. Lipid accumulation and inflammatory response in AML-12 cells and RAW 264.7 macrophages were induced by stimulation with 500 μM free fatty acids (FFA, palmitic-oleic acid mixture 1 : 2) and lipopolysaccharide (LPS, 1 ng/mL) for 24 hours.
Treatment (metformin 0.1 mM, leucine 0.5 mM, and sildenafil 1 nM) was added for further 24 to 48 hours.
Mouse AML-12 liver cells and RAW 264.7 macrophages were seeded together in a ratio 4 : 1. Next day lipid accumulation and inflammatory response were induced by stimulation with 500 μM free fatty acids (palmitic-oleic acid mixture 1 : 2) and LPS (1 ng/mL) for 24 hours. The cells were then treated as indicated for 24 hours.
2.3. MCP1 and TNFα Measurement in Media
AML-12 and/or RAW 264.7 macrophages were seeded and treated as described above. At the end of the treatment, the media were harvested. Monocyte chemotactic protein- (MCP-) 1 and tumor necrosis factor- (TNF-) α secretion was measured with the MCP1 Mouse Elisa kit and TNF-alpha Mouse Elisa kit (Abcam, Cambridge, MA, USA), respectively, according to manufacturer’s instructions.
2.4. Western Blot
The Sirt1, phospho-AMPK (Thr172), AMPK, FAS, SCD1, PPAR-α, and PPARδ, SREBP1, and TNF-α antibodies were obtained from Cell Signaling (Danvers, MA). Protein levels of cell extracts were measured by bicinchoninic acid assay (BCA) kit (Thermo Fisher Scientific Inc., Waltham, MA). For Western blot, 10–50 μg protein was resolved on 4–15% gradient polyacrylamide gels (criterion precast gel, Bio-Rad Laboratories, Hercules, CA), transferred to PVDF or nitrocellulose membranes, incubated in blocking buffer (5% nonfat dry milk in TBS), and then incubated with primary antibody (1 : 1000 dilution), washed, and incubated with horseradish peroxidase- or fluorescence-conjugated secondary antibody (1 : 10000 dilution). Visualization was conducted using Li-COR Odyssey Fc Imaging system (Li-COR Biosciences, Lincoln, NB) and band intensity was assessed using Quantity One (Bio-Rad Laboratories, Hercules, CA), with correction for background and loading controls.
2.5. Fatty Acid Oxidation
Cellular oxygen consumption was measured using a Seahorse Bioscience XF24 analyzer (Seahorse Bioscience, Billerica, MA) in 24-well plates at 37°C. HepG2 cells were seeded at 40,000 cells per well. Lipid accumulation was induced by 48 h incubation with 25 mM glucose. Cells were treated for 24 hours with the indicated treatments, washed twice with nonbuffered carbonate-free pH 7.4 low glucose (2.5 mM) DMEM containing carnitine (0.5 mM), equilibrated with 550 μL of the same media in a non-CO2 incubator for 30 minutes, and then inserted into the instrument for 15 minutes of further equilibration. O2 consumption was measured in three successive baseline measurements at eight-minute intervals prior to injection of palmitate (200 μM final concentration). Post-palmitate-injection measurements were taken over a 3-hour period with cycles consisting of 10 min break and three successive measurements of O2 consumption. The area under the curve was calculated.
2.6. Animals and Diets
Six- to eight-week-old male C57BL/6J mice were purchased from Jackson Laboratories. First NASH was induced in all animals (except low-fat diet control animals (LF)) via feeding of a high-fat atherogenic diet (HC: 60% of calories from fat, 1.25% cholesterol, and 0.5% cholate) for 6 weeks. After this induction period, the HC animals were randomized into one of the following groups with 10 animals/group and kept on their experimental diet for additional 6 weeks (12 weeks total): high-fat atherogenic diet (HC); HC + sildenafil (25 mg/kg diet, calculated as human equivalent dose of 1 mg/day) (HC + Sil); HC + leucine (24 g/kg diet) + sildenafil (HC + Leu + Sil); HC + leucine + metformin (0.25 g/kg diet, calculated as a human equivalent dose of 250 mg/day (HC + Leu + Met)); HC + metformin + sildenafil (HC + Met + Sil); HC + leucine + metformin + sildenafil (HC + Leu + Met + Sil). The LF animals were continued on their diet for an additional 6 weeks.
Animals were housed in polypropylene cages at a room temperature of 22°C and a 12 h light/dark cycle. The animals had free access to water and their experimental food throughout the experiment. Body weight was measured every week. At the end of the treatment period (6 weeks) all animals were humanely euthanized with CO2 inhalation. Blood was collected via trunk bleed and tissues were collected for further experiments as described below.
This study and all animal procedures were performed under the auspices of Institutional Animal Care and Use Committee-Approved protocol of the Georgia State University and in accordance with PHS policy and recommendations of the Guide.
2.7. Liver Histology
Liver tissues were fixed in 10% neutral formalin, embedded in paraffin, and cut into 5 µm sections. Sections were processed for hematoxylin and eosin (H&E) staining and histological images were recorded using Nikon Eclipse E800 Microscopy with Zeiss AxioCam camera.
2.8. Liver Triglyceride Measurements
Liver lipid extraction was conducted as previously described with minor modifications . Briefly, ~100 mg of liver was thawed, minced, and weighted in glass tube. Lipids were extracted in 2 : 1 CHCl3/methanol at room temperature overnight. The lipid portion was then dried down under N2 and redissolved in a measured volume of 2 : 1 CHCl3/methanol. Diluted H2SO4 was added to the sample, which was then vortexed and centrifuged to split the phases. The aqueous upper phase was aspirated and discarded, and an aliquot of the bottom phase was dried down and dissolved in 2% Triton X-100. The triglyceride content was then measured using TG kit/L-Type TG M (Wako Chemicals, USA) and normalized to liver weight.
2.9. ALT Measurement
Serum ALT levels were measured in fed mice after 4 weeks of diet treatment using a mouse ALT ELISA kit from BioVision.
2.10. Liver CD68 and Collagen Staining
Liver tissues were fixed in 10% neutral formalin, embedded in paraffin, and cut into 5 µm sections. For inflammation immunostaining, slides were immunoblotted with CD68 (Bio-Rad MCA 1957) as primary antibody and Biotin-SP-AffiniPure Mouse Anti-Rat IgG as secondary antibody. This was followed by the application of the immunoperoxidase technique with a Vector kit. Areas of staining were quantified with ImageJ and expressed as percentages of the field area. For fibrosis Picro Sirius Red staining, liver slides were dewaxed and hydrated, Weigert's hematoxylin stained for 8 minutes, and Picro-Sirius Red (Picro Sirius Red Stain Kit, Abcam, Cat # ab150681) stained for one hour. Acidified water wash was applied. Slides were dehydrated in three changes of 100% ethanol and cleared in xylene and mounted in a resinous medium. All of the histological images were recorded using Nikon Eclipse E800 Microscopy with Zeiss AxioCam camera. Areas of staining were quantified with ImageJ and expressed as percentages of the field area.
2.11. Gene Expression
2.11.1. In Vitro Data
Cells were grown in a 96-well plate. Cell Lysis, reverse transcription, and RT-PCR were performed using the TaqMan® Gene Expression Cells-to ™ Kit (Life Technologies, Cat # 4399002) according to manufacturer’s instructions. Gene expression was assessed by RT-PCR using StepOnePlus™ PCR system (Thermo Fisher Scientific) and TaqMan Gene expression assays for AMPK (Life Technologies, Cat # Mm01264789) and Sirt1 (Life Technologies, Cat # Mm01168521).
2.11.2. In Vivo Data
Total RNA from liver was extracted using the Tri-Reagent kit (Molecular Research Center, Cincinnati, OH) and gene expression was assessed by quantitative reverse transcription- (RT-) PCR (ABI Universal PCR Master Mix, Applied Biosystems, Foster City, CA) using a Stratagene Mx3000p thermocycler (Stratagene, La Jolla, CA). Cyclophilin was used to normalize the gene expression data. The primer and probe sets used in the assays were purchased from Applied Biosystems/Life Technologies (Grand Island, NY).
2.12. Statistical Analysis
All data are expressed as mean ± SEM. Data were analyzed by one-way ANOVA, and significantly different group means () were separated by the least significant difference test using GraphPad Prism version 6 (GraphPad Software, La Jolla, California, USA, www.graphpad.com).
Based on our previous results in vitro and in vivo showing interacting effects of leucine with either low dose metformin or with PDE5 inhibitors (icariin, sildenafil) on hepatic lipid metabolism, we tested in this study the three-way interaction of leucine, metformin, and sildenafil. As expected, incubation of HepG2 cells with high glucose (25 mM) medium for 48 hours caused significant downregulation of the AMPK/Sirt signaling. This was completely reversed by the three-way combination Sild-Met-Leu while the two-way combinations Met-Leu and Sild-Leu exerted a significant smaller effect (Figures 1(a) and 1(b)). The individual components had no effects. Accordingly, the palmitate-induced oxygen consumption rate in HepG2 cells, measured as a downstream effect of Sirt1/AMPK activation, was significantly increased by the three-way combination. This effect was greater than that exerted by the two-way combinations or by the individual compounds, which had no effect (Figure 1(c)). In addition, gene and protein expressions of lipogenic enzymes (FAS, SCD1 and ACC alpha), which were 2- to 3-fold upregulated after incubation with high glucose medium, were significantly suppressed by Sild-Met-Leu (Figure 2). In addition, the high glucose induced increase of SREBP1, a key transcription factor for lipid synthesis, was reversed by Sild-Met-Leu (Figure 3(c)). In contrast, PPAR alpha and delta, transcription factors regulating fatty acid oxidation, were augmented by Sild-Met-Leu (Figures 3(a) and 3(b)). Moreover, Sild-Met-Leu treatment reduced significantly the ratio of phospho-NF-κB to NF-κB, indicating a reduced inflammatory response (Figure 3(d)).
Next we tested whether these effects could be repeated using a different induction scheme and a different hepatocyte cell line. Induction of lipid accumulation with FFA and LPS had similar effects on Sirt1 and AMPK signaling in HepG2 cells as treatment with high glucose (data not shown). Also, treatment with Sild-Met-Leu increased Sirt1 protein expression in mouse AML-12 hepatocytes and reduced lipogenic protein expression of SREBP1, SCD1, and FAS similar to our observations in HepG2 cells (data not shown). These treatment effects were not caused by significant changes in cell viability (data not shown).
Since the activation of macrophages plays an important role in the pathogenesis of NASH, we used mouse hepatocytes (AML 12 cells) and mouse macrophages (RAW 264.7 cells) as an in vitro model of NASH. To induce lipid accumulation and an inflammatory response, cells were grown individually or in coculture and stimulated with free fatty acids (oleic/palmitic acid mixture) and/or LPS. Stimulation with LPS and FFA reduced both PPAR alpha and delta in coculture (Figures 4(a) and 4(b)) and treatment with Sild-Met-Leu reversed this effect. Sild-Met-Leu also increased PPAR alpha and delta in macrophages (Figures 4(c) and 4(d)), while there was only a trend (27% increase) for PPAR delta and no effect on PPAR alpha (Figures 4(e) and 4(f)) in AML 12 cells. Secretion of the inflammatory mediator MCP-1 was increased after stimulation of cells with FFA only, LPS only, or the combination FFA and LPS. Sild-Met-Leu completely reversed this effect in AML 12 cells and AML/RAW coculture (Figures 5(a) and 5(b)). Sild-Met-Leu also reduced the ratio of phospho-NF-κB/total NF-κB in AML 12 cells to normal control levels. However, the ratio was not changed in RAW macrophages, since Sild-Met-Leu reduced both, total and phospho-NF-κB (Figures 5(c) and 5(d)). In addition, FFA and LPS induced TNF α secretion and protein expression was significantly decreased by Sild-Met-Leu in RAW macrophages (Figures 5(e) and 5(f)).
Based on the in vitro data, we assessed the in vivo effects of Sild-Met-Leu in comparison with Met-Leu, Met-Sild and Sild-Leu in a NASH mouse model. Feeding of a high-fat atherogenic diet (HC) increased liver weight, liver triglycerides, and ALT levels (sixfold), indicating significant hepatocellular injury, while treatment with the Sild-Met-Leu combination significantly blunted these effects. Although the two-way combinations and sildenafil by itself had some effect on ALT levels, the three-way combination exerted a significantly greater effect in comparison with all other groups (Figure 6). Histology staining confirmed a pronounced increase in lipid droplets and ballooned hepatocytes induced by HC diet compared with low-fat diet control. While the two-way combinations attenuated these effects, the triple combination Sild-Met-Leu substantially reversed the steatohepatitis (Figure 7(a)). Moreover, both Met-Leu and Sild-Met-Leu increased PPAR alpha expression in the liver twofold (Figure 7(b)), consistent with activation of hepatic fatty acid oxidation. To assess the level of inflammation in the liver, sections of liver were stained with CD68. The HC diet caused a sixfold increase of CD68 staining in the liver sections, representing a substantial increase in Kupffer cell activation (Figure 8). All two-way combinations significantly attenuated this effect, while only the three-way combination fully reversed it to levels not significantly different from low-fat fed animals (Figure 8). Consistent with this, inflammatory markers such as IL1 beta, TNF-alpha, MCP-1, and PAI-1 were reduced to normal levels by Sild-Met-Leu, but not by the two-way combinations (Figure 9). Next, we assessed fibrosis in liver sections via Sirius Red staining. The increase in fibrotic changes induced by the HC diet was substantially reversed by Sild-Met-Leu and to a lesser degree by the two-way combinations (Figure 10). In accordance with this, gene expressions of the fibrotic markers Col1a1, Col1a2, Col4a1, and TGF-beta were decreased to normal levels by Sild-Met-Leu but only partly reduced by Met-Leu and Sild-Met (Figure 11).
Our data indicate that the triple combination of leucine, metformin, and sildenafil substantially regresses hepatic steatosis, inflammation, and fibrosis and exerts greater effects than the two-way combination, suggesting that this combination may provide a new therapeutic approach to treat NASH.
The pathophysiology of the development of NASH is thought to be a “multihit process,” where multiple environmental, dietary, and genetic factors interact with others . The accumulation of excess lipids in the liver is considered the first step and the prerequisite for subsequent events, which causes progression from simple steatosis to the severe form of NASH in about 30% of patients with NAFLD. Among the other factors contributing to the progression of NASH, inflammation plays an important role . Chronic injury to hepatocytes or hepatocyte death due to excess free fatty acid influx leads to activation of resident macrophages (Kupffer cells) as well as other infiltrating monocytes and macrophages to release proinflammatory cytokines, including TNF-α, IL-1 beta, and IL-6, and profibrogenic factors such as TGF-β which in turn results in activation of hepatic stellate cells and fibrosis progression [26, 27].
The three-way combination Leu-Met-Sild targets the AMPK-Sirt1-eNOS network, as depicted in Figure 12. AMPK, Sirt1, and eNOS are key regulators of hepatic energy and lipid metabolism, as well as inflammation, oxidative stress, and cell proliferation, the key factors for progression of simple NAFLD to NASH and liver fibrosis [2, 14, 28, 29]. Downregulation of Sirt, AMPK, or eNOS promotes the progression of NASH, while activation of this network has been shown to improve hepatic steatosis and inflammation. For example, eNOS-knockout mice fed a high-fat diet showed more extensive hepatic lipid accumulation and inflammation than wild-type mice  and resveratrol treatment, a known Sirt1 and AMPK activator, prevented and reversed lipid accumulation, oxidative stress, and inflammation in vitro and in vivo [31, 32]. We found the triple combination Sild-Met-Leu to upregulate AMPK and Sirt1 and to increase palmitate-stimulated oxygen consumption and decrease the expression of lipogenic genes such as FAS, ACC, and SCD1 in HepG2 cells. Moreover, treatment with Sild-Met-Leu lowered liver triglycerides and reversed the HFD-induced steatosis in mice, the prerequisite condition for developing NASH. In addition, we show a reduction of inflammatory markers in vitro and in vivo as well as a normalization of the CD68 staining in liver samples, a marker expressed by monocytes and macrophages. This was also repeated for F4/80 marker in a follow-up mouse study (data not shown), in which F4/80 was reduced by 40% by Sild-Met-Leu feeding to levels not statistically different from the control low-fat fed animals. Therefore, the triple combination also significantly improves inflammation, one of the key factors for driving progression of the disease. In support of this, the HC-induced fibrosis was totally reversed by supplementation with Sild-Met-Leu, indicated by the percentage of Sirius Red positive area in liver.
AMPK and Sirt1 are well-known regulators of hepatic metabolism. However, there is an increasing body of evidence for a role of eNOS and NO/cGMP signaling in the development of hepatic steatosis, inflammation, and progression to fibrosis [14, 30]. The liver is a highly vascularized tissue and eNOS-derived NO from sinusoidal endothelial cells (SEC) regulate vascular resistance, proliferation, and migration, as well as exerting paracrine effects on adjacent stellate cells. As the first cells exposed to portal vein components and bacterially derived lipopolysaccharides (LPS) from the gut, SECs can undergo dramatic phenotype changes and can induce inflammation and stellate cell activation . eNOS is constitutively expressed in SEC and NO plays a crucial role in maintaining physiological phenotypes of SECs and stellate cells [14, 34]. NAFLD is associated with decreased eNOS activation . Moreover, endothelial dysfunction and reduced NO production have been found to precede inflammation and fibrosis in a NAFLD rat model . In contrast, activation of eNOS as well as increased NO production ameliorates the progression of NASH-related hepatic fibrosis [36, 37]. We previously demonstrated the amplifying effects of the Met-Leu combination on AMPK signaling and reduction of hepatic steatosis in DIO-mice . Similarly, leucine with PDE5 inhibitors (sildenafil, icariin) increased fat metabolism and reduced hepatic lipid accumulation in DIO-mice which was associated with increased NO production in addition to AMPK/Sirt1 activation, indicating that the actions of the PDE5 inhibitors converge on this pathway [8, 22]. In this study, we demonstrate that the Sild-Met-Leu combination exerts greater effects on inflammatory and fibrogenic parameters than the Met-Leu or the Sild-Leu combination, suggesting that the stimulation of eNOS/NO/cGMP pathway may contribute to additional effects on the AMPK/Sirt1 signaling.
The peroxisome proliferator-activated receptors- (PPAR-) alpha and delta are transcription factors finely regulating energetic fluxes and metabolic pathways . PPAR-α is highly expressed in liver and regulates the rates of fatty acid catabolism and lipogenesis in response to nutritional demands. PPAR-α deficient mice develop more severe hepatic steatosis, inflammation, and NASH when fed a HFD compared to wild-type mice [39, 40], while administration of the PPAR-α agonists reverses hepatic steatosis and fibrosis [41, 42]. PPAR-δ is constitutively expressed and regulates β-oxidation in muscle. In the liver, it controls hepatic glucose and lipoprotein metabolism and exerts anti-inflammatory effects [38, 43]. Beneficial effects of PPAR-δ agonists on improvement of hepatic steatosis and inflammation have been reported in mouse models of NASH . The three-way combination in this study showed significant upregulation of PPAR-α and -δ in vitro and of PPAR-α in the mouse liver. This may be an indirect treatment effect secondary to AMPK/Sirt1 stimulation, since AMPK and Sirt1 interact with PPAR-α and -δ [6, 45, 46].
We recently demonstrated the efficacy of the Met-Leu combination and a combination of leucine with the PDE5 inhibitor icariin in reducing hepatic lipid accumulation and inflammation in a HFD-induced NAFLD mouse model [12, 22]. In this study, we used a high-fat atherogenic diet (60% fat, 1.25% cholesterol, and 0.5% cholate) to induce a more severe form of NASH, as this diet induces hepatic insulin resistance, progressive steatosis, inflammation, and fibrosis over 6 to 24 weeks, mimicking the human disease pathology . The animals used in this study developed a significant steatosis with ~7-fold increase in liver triglycerides, hepatic inflammation, and fibrosis within the 12 weeks of study, which is comparable to other studies using this form of diet to induce NASH [48–50].
There are some limitations to this study. We used different forms of induction for the lipid accumulation in HepG2 (high glucose) and AML cells (high concentration of FFA), which limits the ability to compare results between these cell lines. Moreover, AML and RAW cells were stimulated with FFA, LPS, or a combination of both in different experiments, although we show in Figure 3(a) that there was a comparable effect. Finally, not all in vitro parameters were measured in vivo due to limited tissue availability and since we had demonstrated AMPK/Sirt1 activation already previously for the two-way combinations in mice studies [12, 22].
In summary, we demonstrate the beneficial effects of the three-way combination Sild-Met-Leu on the reversal of hepatic steatosis, inflammation, and fibrosis in a NASH mouse model and that all the three components are necessary for maximal effect. These effects are mediated by targeting the AMPK/Sirt1/eNOS network from multiple sites, each contributing a modest effect to the overall outcome, as summarized in Figure 12. This approach allows a substantial dose reduction of each individual compound to a concentration, which has little or no independent effect on the measured outcomes. Therefore, the risk of associated adverse effects of the individual compounds will be diminished. Based on the pivotal role of the AMPK/Sirt1/eNOS network in hepatic metabolism and the promising results of this animal study, the Sild-Met-Leu combination provides a new therapeutic approach to treat NAFLD and NASH.
|eNOS:||Endothelial nitric oxide synthase|
|cGMP:||Cyclic guanosine monophosphate|
|sGC:||Soluble guanylate cyclase|
|PKGs:||cGMP-dependent protein kinases|
The funders had no role in data collection and analysis but were involved in study design, decision to publish, and preparation of the manuscript.
Antje Bruckbauer, Jheelam Banerjee, and Michael B. Zemel are employees and stockholders of NuSirt Biopharma Inc. Antje Bruckbauer and Michael B. Zemel also have patents related to the reported work. All other authors have declared that no competing interests exist.
Financial support was provided by NuSirt Biopharma Inc. (http://nusirt.com). Bingzhong Xue and Hang Shi received funds from NuSirt Biopharma to conduct the animal study.
- A. J. Sanyal, E. M. Brunt, D. E. Kleiner et al., “Endpoints and clinical trial design for nonalcoholic steatohepatitis,” Hepatology, vol. 54, no. 1, pp. 344–353, 2011.
- Y. Colak, O. Ozturk, E. Senates et al., “SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease,” Medical Science Monitor, vol. 17, no. 5, pp. HY5–HY9, 2011.
- P. Dietrich and C. Hellerbrand, “Non-alcoholic fatty liver disease, obesity and the metabolic syndrome,” Best Practice & Research: Clinical Gastroenterology, vol. 28, no. 4, pp. 637–653, 2014.
- Q. Lv, Q. Zhen, L. Liu et al., “AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells,” Life Sciences, vol. 131, pp. 23–29, 2015.
- X. Hou, S. Xu, K. A. Maitland-Toolan et al., “SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase,” The Journal of Biological Chemistry, vol. 283, no. 29, pp. 20015–20026, 2008.
- A. Purushotham, T. T. Schug, Q. Xu, S. Surapureddi, X. Guo, and X. Li, “Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation,” Cell Metabolism, vol. 9, no. 4, pp. 327–338, 2009.
- Y. Yamazaki, I. Usui, Y. Kanatani et al., “Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice,” American Journal of Physiology—Endocrinology and Metabolism, vol. 297, no. 5, pp. E1179–E1186, 2009.
- A. Bruckbauer and M. B. Zemel, “Synergistic effects of polyphenols and methylxanthines with leucine on AMPK/Sirtuin-mediated metabolism in muscle cells and adipocytes,” PLoS ONE, vol. 9, no. 2, Article ID e89166, 2014.
- A. Bruckbauer, M. B. Zemel, T. Thorpe et al., “Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice,” Nutrition and Metabolism, vol. 9, article 77, 2012.
- P. W. Caton, N. K. Nayuni, J. Kieswich, N. Q. Khan, M. M. Yaqoob, and R. Corder, “Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5,” Journal of Endocrinology, vol. 205, no. 1, pp. 97–106, 2010.
- W. Xu, Y.-Y. Deng, L. Yang et al., “Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction,” Translational Research, vol. 166, no. 5, pp. 451–458, 2015.
- L. Fu, A. Bruckbauer, F. Li et al., “Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice,” Metabolism: Clinical and Experimental, vol. 64, no. 11, pp. 1426–1434, 2015.
- M. Pasarín, V. La Mura, J. Gracia-Sancho et al., “Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD,” PLoS ONE, vol. 7, article e32785, 2012.
- S. Tateya, N. O. Rizzo, P. Handa et al., “Endothelial NO/cGMP/VASP signaling attenuates kupffer cell activation and hepatic insulin resistance induced by high-fat feeding,” Diabetes, vol. 60, no. 11, pp. 2792–2801, 2011.
- U. Förstermann and W. C. Sessa, “Nitric oxide synthases: regulation and function,” European Heart Journal, vol. 33, no. 7, pp. 829–837, 2012.
- S. G. Chrysant and G. S. Chrysant, “The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension,” Journal of Clinical Hypertension, vol. 14, no. 9, pp. 644–649, 2012.
- A. Das, D. Durrant, F. N. Salloum, L. Xi, and R. C. Kukreja, “PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer,” Pharmacology and Therapeutics, vol. 147, pp. 12–21, 2015.
- B. Musicki, T. J. Bivalacqua, H. C. Champion, and A. L. Burnett, “Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis,” Journal of Sexual Medicine, vol. 11, no. 2, pp. 424–430, 2014.
- I. Mattagajasingh, C.-S. Kim, A. Naqvi et al., “SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 37, pp. 14855–14860, 2007.
- S. Koka, H. S. Aluri, L. Xi, E. J. Lesnefsky, and R. C. Kukreja, “Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 306, no. 11, pp. H1558–H1568, 2014.
- S. Koka, L. Xi, and R. C. Kukreja, “Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts,” Basic Research in Cardiology, vol. 107, no. 2, article 249, 2012.
- L. Fu, F. Li, A. Bruckbauer et al., “Interaction between leucine and phosphodiesterase 5 inhibition in modulating insulin sensitivity and lipid metabolism,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 8, pp. 227–239, 2015.
- E. G. Bligh and W. J. Dyer, “A rapid method of total lipid extraction and purification,” Canadian Journal of Biochemistry and Physiology, vol. 37, no. 8, pp. 911–917, 1959.
- E. Buzzetti, M. Pinzani, and E. A. Tsochatzis, “The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD),” Metabolism, vol. 65, no. 8, pp. 1038–1048, 2016.
- M. Nati, D. Haddad, A. L. Birkenfeld, C. A. Koch, T. Chavakis, and A. Chatzigeorgiou, “The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH),” Reviews in Endocrine and Metabolic Disorders, vol. 17, no. 1, pp. 29–39, 2016.
- M. Sharma, S. Mitnala, R. K. Vishnubhotla, R. Mukherjee, D. N. Reddy, and P. N. Rao, “The riddle of nonalcoholic fatty liver disease: progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis,” Journal of Clinical and Experimental Hepatology, vol. 5, no. 2, pp. 147–158, 2015.
- C. Trautwein, S. L. Friedman, D. Schuppan, and M. Pinzani, “Hepatic fibrosis: concept to treatment,” Journal of Hepatology, vol. 62, no. 1, pp. S15–S24, 2015.
- Z. Yang, B. B. Kahn, H. Shi, and B.-Z. Xue, “Macrophage α1 AMP-activated protein kinase (α1AMPK) antagonizes fatty acid-induced inflammation through SIRT1,” The Journal of Biological Chemistry, vol. 285, no. 25, pp. 19051–19059, 2010.
- J. Xie, X. Zhang, and L. Zhang, “Negative regulation of inflammation by SIRT1,” Pharmacological Research, vol. 67, no. 1, pp. 60–67, 2013.
- Y. Nozaki, K. Fujita, K. Wada et al., “Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution,” BMC Gastroenterology, vol. 15, article 177, 2015.
- G. Ji, Y. Wang, Y. Deng, X. Li, and Z. Jiang, “Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy,” Lipids in Health and Disease, vol. 14, article 134, 2015.
- S. Heebøll, K. L. Thomsen, S. B. Pedersen, H. Vilstrup, J. George, and H. Grønbæk, “Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease,” World Journal of Hepatology, vol. 6, no. 4, pp. 188–198, 2014.
- T. Greuter and V. H. Shah, “Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights,” Journal of Gastroenterology, vol. 51, no. 6, pp. 511–519, 2016.
- G. Xie, X. Wang, L. Wang et al., “Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats,” Gastroenterology, vol. 142, no. 4, pp. 918–927, 2012.
- R. D. Sheldon, M. H. Laughlin, R. S. Rector, J. Padilla, and N. T. Jenkins, “Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats,” Journal of Applied Physiology, vol. 116, no. 9, pp. 1156–1164, 2014.
- W. Wang, C. Zhao, J. Zhou, Z. Zhen, Y. Wang, and C. Shen, “Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis,” PLoS ONE, vol. 8, no. 10, Article ID e76538, pp. 1–11, 2013.
- Z. Dong, L. Su, S. Esmaili et al., “Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells,” Journal of Molecular Medicine, vol. 93, no. 12, pp. 1327–1339, 2015.
- S. Ballestri, F. Nascimbeni, D. Romagnoli, E. Baldelli, and A. Lonardo, “The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans,” Advances in Therapy, vol. 33, no. 3, pp. 291–319, 2016.
- A. Montagner, A. Polizzi, E. Fouché et al., “Liver PPARa is crucial for whole-body fatty acid homeostasis and is protective against NAFLD,” Gut, vol. 65, pp. 1202–1214, 2016.
- E. Ip, G. C. Farrell, G. Robertson, P. Hall, R. Kirsch, and I. Leclercq, “Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice,” Hepatology, vol. 38, no. 1, pp. 123–132, 2003.
- S. Barbosa-Da-Silva, V. Souza-Mello, D. C. Magliano, T. D. S. Marinho, M. B. Aguila, and C. A. Mandarim-De-Lacerda, “Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice,” Life Sciences, vol. 127, pp. 73–81, 2015.
- E. Ip, G. Farrell, P. Hall, G. Robertson, and I. Leclercq, “Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice,” Hepatology, vol. 39, no. 5, pp. 1286–1296, 2004.
- S. Liu, B. Hatano, M. Zhao et al., “Role of peroxisome proliferator-activated receptor /β in hepatic metabolic regulation,” Journal of Biological Chemistry, vol. 286, no. 2, pp. 1237–1247, 2011.
- H. J. Lee, J. E. Yeon, E. J. Ko et al., “Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 21, no. 45, pp. 12787–12799, 2015.
- L. Serrano-Marco, M. R. Chacón, E. Maymó-Masip et al., “TNF-α inhibits PPARβ/δ activity and SIRT1 expression through NF-κB in human adipocytes,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1821, no. 9, pp. 1177–1185, 2012.
- V. A. Narkar, M. Downes, R. T. Yu et al., “AMPK and PPARδ agonists are exercise mimetics,” Cell, vol. 134, no. 3, pp. 405–415, 2008.
- S. H. Ibrahim, P. Hirsova, H. Malhi, and G. J. Gores, “Animal models of nonalcoholic steatohepatitis: eat, delete, and inflame,” Digestive Diseases and Sciences, vol. 61, no. 5, pp. 1325–1336, 2016.
- M. Ichimura, M. Kawase, M. Masuzumi et al., “High-fat and high-cholesterol diet rapidly induces non-alcoholic steatohepatitis with advanced fibrosis in Sprague-Dawley rats,” Hepatology Research, vol. 45, no. 4, pp. 458–469, 2015.
- K. Mukai, T. Miyagi, K. Nishio et al., “S100A8 production in CXCR2-expressing CD11b+Gr-1high cells aggravates hepatitis in mice fed a high-fat and high-cholesterol diet,” Journal of Immunology, vol. 196, no. 1, pp. 395–406, 2016.
- N. Matsuzawa, T. Takamura, S. Kurita et al., “Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet,” Hepatology, vol. 46, no. 5, pp. 1392–1403, 2007.
Copyright © 2016 Antje Bruckbauer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.